XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.24.3

Shareholders' Equity | 9 Months Ended
--- | ---
Sep. 30, 2024
Shareholders' Equity |
Shareholders' Equity |
| 6. | Shareholders’ Equity
Business Combination Immediately prior to the Closing Date of the Business Combination, Pfizer was issued additional Series A-1 convertible preferred shares upon the closing of the Business Combination that were immediately converted to 267,939 Class A Ordinary Shares. The shares were issued in accordance with the anti-dilution provision of the Pfizer Agreement. On the Closing Date and in accordance with the terms and subject to the conditions of the Business Combination, each Class A Ordinary Share of Legacy Zura, par value $0.001 per share, Series A-1 convertible preferred share, outstanding option (whether vested or unvested), and restricted share unit (whether vested or unvested) were canceled and converted into a comparable number of awards that consisted of either the rights to receive or acquire the Company’s Class A Ordinary Shares, par value $0.0001 per share, as determined by the exchange ratio pursuant to the Business Combination Agreement. The exchange ratio is approximately 108.083. On March 16, 2023, in connection with the closing of the Business Combination and effective upon the Closing Date, the Company authorized 300,000,000 Class A Ordinary Shares, par value of $0.0001 and 1,000,000 preferred shares, par value of $0.0001. Shelf Registration and ATM Program The Company filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”), which was declared effective on September 17, 2024. Pursuant to the Shelf Registration Statement, the Company may offer and sell ordinary shares, preference shares, debt securities, warrants and or units having an aggregate public offering price of up to $300.0 million. In connection with the filing of the Shelf Registration Statement, the Company also entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), relating to the sale of the Company’s Class A Ordinary Shares having an aggregate gross sales price of up to $125.0 million, from time to time through Leerink Partners, acting as sales agent (the “ATM”). The Company incurred $0.6 million of offering expenses in connection with establishing the ATM that reduced additional paid-in capital as of September 30, 2024. On September 18, 2024, the Company sold 1,500,000 Class A Ordinary Shares at a price of $3.80 per share under the ATM, for net proceeds of $5.5 million, after underwriting commissions. Warrant Exchange In connection with the Warrant Exchange, the Company issued 3,782,190 Class A Ordinary Shares. See Note 7. Exchange of Class A Ordinary Shares On August 15, 2024, the Company entered into a share surrender and warrant agreement (the “Share Exchange Agreement”) with certain affiliated shareholders (the “Shareholders”), pursuant to which (i) the Shareholders surrendered an aggregate of 4,000,000 Class A Ordinary Shares owned by the Shareholders, for no consideration, which were immediately cancelled and retired, upon surrender; and (ii) the Company issued pre-funded warrants to purchase an aggregate of 4,000,000 Ordinary Shares, with an exercise price of $0.001 per share (the “Share Exchange Warrants”) (the “Share Exchange”). April 2024 Private Placement On April 18, 2024, the Company entered into subscription agreements (the “Investor Agreements”) with certain institutional and other accredited investors (the “Investors”), whereby the Company agreed to issue 18,732,301 Class A Ordinary Shares at a price of $3.108 per share and pre-funded warrants to purchase up to 16,102,348 Class A Ordinary Shares (the “2024 Pre-Funded Warrants”) at a price of $3.107 per 2024 Pre-Funded Warrant for an aggregate purchase price of $108.3 million. See Note 7 for further information about the 2024 Pre-Funded Warrants. On April 18, 2024, the Company also entered into subscription agreements (the “Insider Agreements” and together with the Investor Agreements, the “April 2024 Private Placement”) with certain officers, directors and affiliates of the Company (“Insiders” and together with the Investors, the “Subscribers”), whereby the Company issued 1,357,827 Class A Ordinary Shares at a price of $3.13 per share for an aggregate purchase price of $4.2 million. The April 2024 Private Placement closed on April 22, 2024, from which the Company received total gross proceeds of approximately $112.5 million, before deducting transaction costs of $7.2 million. Ordinary Shares Reserved for Issuance A summary of shares reserved for issuance as of September 30, 2024 is summarized below: ​
​ | ​ | ​
​ |  | September 30, 2024
Shares issuable upon exercise of warrants to purchase Class A Ordinary Shares |  | 23,884,348
Shares issuable upon exercise of options to purchase Class A Ordinary Shares |  | 11,308,838
Shares available for grant under 2023 Equity Incentive Plan and 2023 Employee Share Purchase Plan |  | 2,711,586
Shares issuable upon exercise of Z33 Series Seed Preferred Shares Put Right |  | 2,000,000
Shares issuable upon release of restricted share units |  | 1,056,720
Total shares reserved for issuance |  | 40,961,492
​

X
- References No definition available. + Details
Name: | zura_TemporaryEquityDisclosureAndStockholdersEquityNoteDisclosureAbstract
Namespace Prefix: | zura_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for temporary equity and shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income + References No definition available. + Details
Name: | zura_TemporaryEquityDisclosureAndStockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | zura_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration